Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

(2014) Terence O'Reilly et al.   Translational Oncology

Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer

(2013) Parthasarathy Seshacharyulu et al.   CANCER LETTERS

Proliferation-Independent Control of Tumor Glycolysis by PDGFR-Mediated AKT Activation

(2013) C. Ran et al.   CANCER RESEARCH

Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures

(2013) Elisa Carra et al.   CELL CYCLE

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

(2013) J. Lin et al.   CLINICAL CANCER RESEARCH

RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

(2013) Prakash Chinnaiyan et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Glioma is formed by active Akt1 alone and promoted by active Rac1 in transgenic zebrafish

(2013) In Hye Jung et al.   NEURO-ONCOLOGY

Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells

(2013) Y. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IGF1 Receptor Signaling Regulates Adaptive Radioprotection in Glioma Stem Cells

(2013) Satoru Osuka et al.   STEM CELLS

Knockdown of AKT2 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to the anticancer drug VM-26 in U87 glioma cells

(2012) Yong Cui et al.   BRAIN RESEARCH

The Definition of Primary and Secondary Glioblastoma

(2012) H. Ohgaki et al.   CLINICAL CANCER RESEARCH

Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma

(2012) Ravi S. Narayan et al.   CURRENT PHARMACEUTICAL DESIGN

Gefitinib Radiosensitizes Stem-Like Glioma Cells: Inhibition of Epidermal Growth Factor Receptor-Akt-DNA-PK Signaling, Accompanied by Inhibition of DNA Double-Strand Break Repair

(2012) Khong Bee Kang et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics

(2012) Kiran Mahajan et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells

(2012) P. B. Makhov et al.   MOLECULAR CANCER THERAPEUTICS

PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome

(2012) S. Mueller et al.   NEURO-ONCOLOGY

Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era

(2012) Christine Carico et al.   PLoS One

Nonredundant Functions for Akt Isoforms in Astrocyte Growth and Gliomagenesis in an Orthotopic Transplantation Model

(2011) R. Endersby et al.   CANCER RESEARCH

FOXO1 Inhibits Runx2 Transcriptional Activity and Prostate Cancer Cell Migration and Invasion

(2011) H. Zhang et al.   CANCER RESEARCH

MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks

(2011) Michael Fraser et al.   CELL CYCLE

The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling

(2011) Yi-fang Ping et al.   JOURNAL OF PATHOLOGY

MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis

(2011) Y. Cheng et al.   MOLECULAR CANCER THERAPEUTICS

Akt2 and Akt3 play a pivotal role in malignant gliomas

(2011) H. Mure et al.   NEURO-ONCOLOGY

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide

(2011) G. Prasad et al.   NEURO-ONCOLOGY

Expression of pERK and pAKT in pediatric high grade astrocytomas: Correlation with YKL40 and prognostic significance

(2011) Manila Antonelli et al.   NEUROPATHOLOGY

Sphingosine Kinase 1 Regulates the Akt/FOXO3a/Bim Pathway and Contributes to Apoptosis Resistance in Glioma Cells

(2011) Hongyu Guan et al.   PLoS One

PI3K/Akt signaling requires spatial compartmentalization in plasma membrane microdomains

(2011) X. Gao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma

(2010) Erika F. Rodriguez et al.   ACTA NEUROPATHOLOGICA

Preclinical Evaluation of Radiation and Perifosine in a Genetically and Histologically Accurate Model of Brainstem Glioma

(2010) O. J. Becher et al.   CANCER RESEARCH

Loss of PTEN Binding Adapter Protein NHERF1 from Plasma Membrane in Glioblastoma Contributes to PTEN Inactivation

(2010) J. R. Molina et al.   CANCER RESEARCH

Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas

(2010) Guangxiu Wang et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide

(2010) Won Jun Oh et al.   EMBO JOURNAL

Akt inhibitors in clinical development for the treatment of cancer

(2010) Sumanta Kumar Pal et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme

(2010) Jann N. Sarkaria et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Higher pAkt Expression Predicts a Significant Worse Prognosis in Glioblastomas

(2010) Yoshiyuki SUZUKI et al.   JOURNAL OF RADIATION RESEARCH

Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells

(2010) Gowry Das et al.   MOLECULAR CARCINOGENESIS

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study

(2010) N. Butowski et al.   NEURO-ONCOLOGY

Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy

(2009) Ryan J.O. Dowling et al.   BIODRUGS

EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma

(2009) B. Mukherjee et al.   CANCER RESEARCH

Akt-dependent and -independent mechanisms of mTOR regulation in cancer

(2009) Regan M. Memmott et al.   CELLULAR SIGNALLING

Reduction of Akt2 inhibits migration and invasion of glioma cells

(2009) Baogang Zhang et al.   INTERNATIONAL JOURNAL OF CANCER

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Stimulation of Glioma Cell Survival Is Dependent on Akt2 Function

(2009) S. P. Fortin et al.   MOLECULAR CANCER RESEARCH

Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells

(2009) G. L. Gallia et al.   MOLECULAR CANCER THERAPEUTICS

Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α

(2009) A Soeda et al.   ONCOGENE

AKT Signaling in Regulating Angiogenesis

(2008) Bing-Hua Jiang et al.   CURRENT CANCER DRUG TARGETS

The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C

(2008) Valeria Facchinetti et al.   EMBO JOURNAL

Runx2 is expressed in human glioma cells and mediates the expression of galectin-3

(2008) Valentina Vladimirova et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Antiangiogenics and radiotherapy

(2008) Aoife M. Shannon et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma

(2008) J. S. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK)

(2008) L. A. Edwards et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

PI3K/Akt: getting it right matters

(2008) T F Franke   ONCOGENE